Connect with Industry
Virtual Patent Awards Ceremony 2021:
“Innovation in the Time of COVID-19: Meeting the Challenge” – If you missed it, catch the full event here!
Continuity of Service
Our office remains committed to providing our standard level of excellent service. At this time, due to the fluid situation of the coronavirus pandemic, we will do so virtually, rather than in-person, during our regular business hours. To reach the Office of Technology Commercialization, please call 202.687.7424 or email email@example.com and Jeremy Alexander at firstname.lastname@example.org . Someone will respond to you promptly.
More information on COVID-19 related agreements can be found on the following link: https://otc.georgetown.edu/covid19-contracts/
Office of Technology Commercialization (OTC) manages Georgetown University invention disclosures, patenting and licensing activities, research collaboration agreements, material transfer agreements, confidentiality agreements, data use agreements, copyright and intellectual property agreements between the University and faculty, engagement of Georgetown University in the founding of startup companies, and assistance to University entrepreneurs in starting their own companies. If you believe that you have an invention, it is critical that you disclose the invention to OTC immediately, and prior to any publication or public presentation of the invention.
- About Us
- For Georgetown Inventors – Reporting an invention and other resources
- Industry Collaboration Opportunities for Georgetown Principal Investigators
- For Industry – Technology Licensing Opportunities
- Startup Guidance – For Georgetown Inventors and Entrepreneurs
- Events – List of events we host throughout the year
Top Stories From OTC
The Georgetown University Medical Center (GUMC) Office of the Dean for Research is proud to present the Dean’s Seminar Series. For more information on upcoming speakers, times and dates please visit the following link: https://biomedicalresearch.georgetown.edu/seminar-series/
Upcoming I2Is and Events:
In our monthly I2I (Invention to Innovation) event, OTC had the pleasure of hosting George Likourezos, J.D. and Dr. Carmella L. Stephens, Ph.D., J.D. from Carter, Deluca, & Farrell LLP. Georgetown University faculty and staff had the opportunity to learn more about IP protection for AI-implemented Life Sciences inventions and how University Entrepreneurs can prepare for commercialization of their technologies.
“Speed dating” for Innovation: OTC hosted an event where researchers and entrepreneurs with ideas had the opportunity to network with investors looking for ideas, enabling them to meet a large number of potential partners in a short amount of time
Research and Engagement
A Fast and Accurate COVID-19 Test: Georgetown University researchers have engineered a next generation pathogen detection system that has been shown to be extremely sensitive and specific and therefore to have extremely low false positive and false negative rates. It is as rapid or faster than other methods and can also be automated and used to test for multiple types of organisms simultaneously (“multiplexed”). We are kindly asking your support of this campaign that will allow researchers to use this groundbreaking technology to develop a high-fidelity rapid molecular test for detecting the COVID-19 virus. To support this campaign for a faster, more accurate COVID-19 test please visit the following link: https://www.givecampus.com. We appreciate your consideration of making a gift and sharing this important work with others who may also be interested in doing so.
Georgetown University (GU) continues to collaborate with George Washington University (GW) to help build the DC entrepreneurial community. We have been invited to join the “GWCAN” (More information can be found on the following link: https://giveandtakeinc.com/givitas-for-gwcan/). GW welcomes inventors, investors, new entrepreneurs and experienced entrepreneurs to explore the opportunities provided through the network. For more questions, contact the Office of Technology Commercialization, please call 202.687.7424 or email email@example.com.
Procter & Gamble is seeking solutions for a Biodegradable and Stable Polymers which will retain its physical properties when in contact with sterile aqueous formulations for up to 24 months at 38C and Liquid Compatible Barrier for packages which contain aqueous liquid product formulations the packaging must also provide an impermeable barrier to water loss under tropical conditions (MVTR < 1g/m2/day at 38C/90% RH).
Please reach out to Steve Bullock (firstname.lastname@example.org) if you have additional questions and/or are aware of potential solutions/partners that might meet this need. They are looking for potential solutions by June 1, 2021.
Note to GU Inventors: Please contact OTC (email@example.com) first if you have any technologies that address these needs.
Harrington Discovery Institute (HDI) invites you to submit an LOI for the 2022 Harrington Scholar-Innovator Award. This grant supports all disease areas and is designed to advance your promising drug discovery research towards the clinic. Letters of Intent (LOI) Due on April 16, 2021. To submit application please visit the following link: HDI’s grant system.
The U.S. Army is now accepting Concept White Paper submissions for its newest prize competition, the xTech Small Business Innovation Research (SBIR) Waveform Challenge, with the opportunity to earn prize money and potential to submit for a Phase I SBIR or Direct to Phase II (D2PhII) SBIR award. Concept White Paper submissions must be received by 8:00 AM EST April 13, 2021. If you are interested in participating in the xTechSBIR Waveform Challenge competition, please visit the Army xTech website at www.xtechsearch.army.mil for further details.
Harrington Discovery Institute (HDI) and the Alzheimer’s Drug Discovery Foundation (ADDF) invite you to submit an LOI for the 2021 ADDF-Harrington Scholar Award. This grant is designed to accelerate the translation of academic discoveries into medicines for treating, preventing, or curing patients with Alzheimer’s disease and related dementias. Of particular interest are targets related to proteostasis and epigenetics. Researchers working on drug development programs that are relevant to, but not presently focused on, the Alzheimer’s field are encouraged to apply. Letters of Intent (LOI) Due on April 23, 2021. To submit application please visit the following link: ADDF’s funding system.
Johnson & Johnson Innovation – JLABS @ Washington, DC is the newest Johnson & Johnson Innovation – JLABS life science and healthcare incubator. The state-of-the-art site will be open to entrepreneurs and innovators, and startups, focused on innovation across the healthcare spectrum, including pharmaceuticals, medical device, consumer and health tech. . Please review Johnson & Johnson Innovation’s areas of interests prior to applying to ensure your technology is aligned to what they are looking for at this time: https://jnjinnovation.com/partnering
For more information on J&J Innovation please visit the following link
Blue Knight | JLABS – Johnson & Johnson Innovation – JLABS is collaborating with the Biomedical Advanced Research and Development Authority (BARDA), a component of the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services to form Blue Knight. This collaboration aims to stimulate innovation and incubation of technologies that improve health security and response through companies focused on public health threats and emerging infectious diseases. For more information on Blue Knight please visit the following link.
National Academy of Inventors (NAI) Announces Launch of Free Online IP Course. With this course you will be able to:
-Explain the basics of intellectual property policies.
-Understand how intellectual property protections benefit individual creators, business owners, and entrepreneurs.
-Describe the relationship between intellectual property protection and economic growth.
-Discuss the historical origins of intellectual property law in the United States
More information can be found on the following link: NAI IP Course
Below is the list of IN-PART‘s available opportunities. If you are interested in responding to these campaigns, please contact our office (firstname.lastname@example.org) for assistance.
Physical Science (Industrial Chemistry):
Seeking Novel Techniques, Processes and Materials for Catalysis and Industrial Chemistry (new window) – Anonymous, Deadline 15th March. (Global)|
Novel Therapeutic Approaches Targeting Microglia Biology for Neuroinflammatory Disorders (new window) – Astellas, Deadline 15th March. (Global)
Seeking Novel Research Programmes to Induce Specific Tregs in vivo (new window) – Anonymous, Deadline 15th March. (Global)
Seeking Phenotypic Cellular Assays Relating to Neuroscience (new window) – Takeda, Deadline 5th April. (Europe, North America and Oceania only)
Seeking Phenotypic Cellular Assays Relating to Gastroenterology (new window) – Takeda, Deadline 5th April. (Europe, North America and Oceania only)
Seeking Phenotypic Cellular Assays Relating to Oncology (new window) – Takeda, Deadline 5th April. (Europe, North America and Oceania only)
Seeking Phenotypic Cellular Assays Relating to Rare Disease (new window) – Takeda, Deadline 5th April. (Europe, North America and Oceania only)
- Nilotinib Appears Safe and Affects Biomarkers in Alzheimer’s Disease Clinical Trial
- New Drug Prevents Liver Damage, Obesity and Glucose Intolerance in Mice on High-Fat Diet
- Nilotinib Appears Safe in Parkinson’s Trial; Drug Thought to Allow Dopamine Replenishment
- Obese Mice Lose a Third of Their Fat Using a Natural Protein
- Researchers Find Inhibiting One Protein Destroys Toxic Clumps Seen in Parkinson’s Disease
- Other Stories Here
What is Technology Commercialization/ Technology Transfer?
Watch the Association of University Technology Managers (AUTM)’s site and video featuring the ins and outs of Technology Transfer and learn more about what is involved in its process.